髓系细胞触发受体2(TREM2)在急慢性肝病中的作用  

Role of triggering receptor expressed on myeloid cells 2 in acute and chronic liver diseases

作　　者：崔馨月[1] 孙全昊 郑丽红[2] 王海强[3] CUI Xinyue;SUN Quanhao;ZHENG Lihong;WANG Haiqiang(The First Clinical College of Heilongjiang University of Chinese Medicine,Harbin 150040,China;Department of Gastroenterology,The Fourth Affiliated Hospital of Heilongjiang University of Chinese Medicine,Harbin 150001,China;Second Department of Gastroenterology,The First Affiliated Hospital of Heilongjiang University of Chinese Medicine,Harbin 150040,China)

机构地区：[1]黑龙江中医药大学第一临床医学院,哈尔滨150040 [2]黑龙江中医药大学附属第四医院消化内科,哈尔滨150001 [3]黑龙江中医药大学附属第一医院消化二科,哈尔滨150040

出　　处：《临床肝胆病杂志》2025年第2期383-388,共6页Journal of Clinical Hepatology

基　　金：国家中医药管理局第五批全国中医临床优秀人才研修项目(国中医药人教函[2022]1号);黑龙江中医药大学“优秀青年骨干教师”计划(15041190018)。

摘　　要：在肝脏中髓系细胞触发受体2(TREM2)表达于常驻非实质细胞,参与肝脏炎症、免疫调控等病理过程。近年来,TREM2在急慢性肝病研究领域中受到关注,且越来越多的研究表明TREM2是治疗急慢性肝病的潜在靶点,然而其在急慢性肝病中的作用机制缺乏系统性的总结。本文综述了TREM2在急慢性肝病中调控作用的最新研究进展,以期为临床防治急慢性肝病提供新思路。Triggering receptor expressed on myeloid cells 2(TREM2)is expressed in resident non-parenchymal cells(NPCs)and is involved in various pathological processes including liver inflammation and immunoregulation.In recent years,TREM2 has attracted attention in the field of acute and chronic liver diseases,and more and more studies have shown that TREM2 is a potential target for the treatment of acute and chronic liver diseases;however,there is a lack of systematic summary for the mechanism of action of TREM2 in acute and chronic liver diseases.Therefore,this article reviews the latest research advances in the regulatory role of TREM2 in acute and chronic liver diseases,in order to provide new ideas for the clinical prevention and treatment of acute and chronic liver diseases.

关 键 词：髓系细胞触发受体2 肝疾病 病理过程 

分 类 号：R575[医药卫生—消化系统]